ZY19489+ ferroquine

Product development

-

Patient exploratory

Zydus

Asexual blood stages

Uncomplicated malaria treatments and resistance management (TPP-1)

Product vision	Uncomplicated malaria treatment and resistance management
MOA	ZY19489 new class of inhibitors, no resistance detected in vitro, mechanism of action unknown Ferroquine (FQ), a 4-aminoquinoline: inhibition of haem detoxification
Key features	ZY19489: No stable resistance detected in in vitro or clinical studies FQ: long duration of plasma exposure, fully active against amodiaquine and piperaquine resistant strains
Challenges	ZY19489: Synthesis and cost of goods
Status	ZY19489 phase I Multiple Ascending Dose completed in 2022 FQ: Two phase II studies in combination with OZ439 were completed in 2020; discovered by CNRS Lille and transferred to Sanofi; rights transferred from Sanofi to MMV
Next milestone	Initiate phase IIb combination study
Previously	ZY19489 discovery partnership between MMV and AstraZeneca, Bangalore ZY19489 name AZ13721412; full reference name is MMV674253
Project Director	Dr Cristina Donini